Probiotic supplementation reduces systemic inflammation in dialysis patients: the effect on circulating regulatory T-cells and pro-inflammatory monocytes

doi:10.21203/rs.3.rs-140039/v1

Download PDF

Research

Probiotic supplementation reduces systemic inflammation in dialysis patients: the effect on circulating regulatory T-cells and pro-inflammatory monocytes

https://doi.org/10.21203/rs.3.rs-140039/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

Emerging evidence suggests that intestinal dysbiosis contributes to systemic inflammation and cardiovascular diseases in dialysis patients. The purpose of this study was to evaluate the effects of probiotic supplementation on various inflammatory parameters in hemodialysis (HD) patients.

Methods

Twenty-two patients with maintenance HD were enrolled (Institutional Review Board No. 2018AN0346). These patients were treated twice a day with 2.0 × 10¹⁰ colony forming units of a combination of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI for 3 months. The microbiome and fecal short chain fatty acids (SCFAs) were analyzed. The percentages of CD14⁺ CD16⁺ pro-inflammatory monocytes, and CD4⁺ CD25⁺ regulatory T-cells (Tregs) before and after probiotic supplementation were determined by flow cytometry. Serum levels of calprotectin and cytokine responses upon lipopolysaccharide (LPS) challenge were compared before and after probiotic supplementation.

Results

Fecal SCFAs increased significantly after probiotic supplementation. Serum levels of calprotectin and IL-6 upon LPS stimulation significantly decreased. The anti-inflammatory effects of probiotics were associated with a significant increase in the percentage of CD4⁺ CD25⁺ Tregs (3.5% vs 8.6%, p < 0.05) and also with a decrease of CD14⁺ CD16⁺ pro-inflammatory monocytes (310 vs. 194/mm², p < 0.05).

Conclusion

Probiotic supplementation reduced systemic inflammatory responses in HD patients and this effect was associated with an increase in Tregs and a decrease in pro-inflammatory monocytes. Hence, targeting intestinal dysbiosis might be a novel strategy for decreasing inflammation and cardiovascular risks in HD patients.

Trial registration

The study was retrospectively registered in Clinical Research Information Service (CRIS) (KCT0005417) (09/09/2020).

Nutrition & Dietetics

probiotics

inflammation

monocytes

Tregs

short chain fatty acids

Maladaptive and persistent inflammation has been recognized as an important player in the development of cardiovascular diseases and also as a predictor of mortality in patients with chronic kidney disease (CKD)[1–4]. Although not completely understood, retention of uremic solutes, oxidative stress, immune dysfunction, or dialysis-related factors including repeated exposure to dialysis membranes, contaminated dialysis water, and recently, intestinal dysbiosis, have been implicated as important culprits in the development of chronic inflammation.

Significant alterations in the diversity and number of operational taxonomic units (OTUs) associated with increased intestinal permeability have been demonstrated in preclinical and clinical studies. Uremic milieu, slower colonic transit time, bowel edema due to volume overload, restrictions of fiber-rich diets, medications including phosphate binders, and frequent use of antibiotics might be factors contributing to the generation and maintenance of dysbiosis [5–8].

Probiotics are “live microorganisms that, when administered in adequate amounts, confer a health benefit to the host” [9]. Probiotics have been shown to partially restore normal intestinal microbiota and reduce the level of uremic toxins and systemic inflammation. A recent study by Soleiman et al., showed improvement of glycemic control and reductions in C-reactive proteins (CRP) in diabetic patients undergoing HD [10]. One of the mechanisms of probiotic-induced anti-inflammatory effects might be mediated by probiotic-induced immune modulation.

CD4⁺ CD25⁺ regulatory T-cells (Tregs) are a subpopulation of T-cells with regulatory function and have been demonstrated to be effective in reducing inflammation. CD14⁺ CD16⁺ nonclassical monocytes are a subset of pro-inflammatory monocytes which increase in advanced CKD patients. Lee et al., previously demonstrated a positive correlation between these cells and vascular stiffness, suggesting the possible important role of this monocyte subset in increased cardiovascular risks in CKD patients [11].

The purpose of this study was to assess the effect of probiotic supplementation on chronic inflammation in maintenance HD patients. We analyzed the microbiome, fecal short chain fatty acids (SCFAs), and inflammatory responses before and 3 months after probiotic supplementation. The percentage of circulating Tregs and the number of CD14⁺ CD16⁺ monocytes were also measured by flow cytometry. The effect of probiotic supplementation on these parameters was also examined 4 months after the discontinuation of probiotics.

Study design

Enrolled patients included those aged > 18 years undergoing maintenance dialysis for more than 3 months at Korea University Anam Hospital, a tertiary hospital in Seoul, South Korea, from Nov to Dec 2018. Exclusion criteria were patients who: (a) were on HD for acute kidney injury; (b) were on HD less than twice per week; (c) had uncontrolled diarrhea or gastrointestinal infection; (d) were treated with oral or intravenous antibiotics within 4 weeks of enrollment; and (e) were actively being treated for cancer, or with immunosuppressive drugs. Among the 23 patients providing informed consent, 1 patient withdrew from the study and 22 patients completed the trial. These patients were treated with sachets [2 g mixtures of probiotics containing 7.0×10⁹ colony forming units (CFU)/g of Bifidobacterium bifidum BGN4 and 2.0×10⁹ CFU/g of Bifidobacterium longum BORI] twice per day for 3 months. B. bifidum BGN4 and B. longum BORI were isolated from the feces of healthy breast-fed infants, and have been used as probiotics since 2000 [12–16]. Its complete genomic sequence was reported to GenBank [17]. B. longum BORI has been shown to shorten the duration of diarrhea in a clinical study of infants infected with rotavirus [12]. A safety assessment of B. bifidum BGN4 and B. longum BORI concerning ammonia production, hemolysis of blood cells, biogenic amine production, antimicrobial susceptibility patterns, antibiotic resistance gene transferability, polymerase chain reaction (PCR) data on antibiotic resistance genes, mucin degradation, genome stability, and the presence of virulence factors has been recently reported [18] Both strains have been considered Generally Recognized As Safe by the United States Food and Drug Administration (US FDA) (GRN813 for B. longum BORI and GRN814 for B. bifidum BGN4; https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices). Blood and fecal samples were obtained at baseline and at 3 and 6 months. The study protocol was approved by the Korea University Medical Center Institutional Review Board (IRB No. 2018AN0346) Written informed consent was provided by all participants.

Laboratory measurements

Routine laboratory measurements including complete blood counts with white blood cell differentials, CRP, albumin, blood urea nitrogen, creatinine, and electrolytes were obtained before the dialysis session. Patients’ demographic factors and current medications were also recorded.

Blood and fecal samples were centrifuged at 2,500×g for 15 min and stored at -80 ^OC for calprotectin measurements. Samples were analyzed using an enzyme-linked immunosorbent assay (ELISA - LSBio, LS-F9275, Seattle, WA, USA) according to the manufacturer’s instructions.

Flow cytometric detection of Tregs and pro-inflammatory monocyte subsets

Blood samples were collected before the dialysis session. Whole blood (2.5 ml) was collected in a heparinized tube and 200 µl aliquots of heparinized blood were stained for 15 min at room temperature with either anti-human CD4 conjugated with allophycocyanin (CD4-APC), anti-human CD25 conjugated with phycoerythrin (CD25-PE) antibodies for detection of Tregs, anti-human CD14 conjugated with fluorescein isothiocyanate (CD14-FITC), or anti-human CD16 conjugated with allophycocyanin (CD16-APC) antibodies for the detection of monocytes (BD Biosciences, San Jose, CA, USA). After red blood cell lysis and washing, flow cytometric detection of Tregs and the CD14⁺ CD16⁺ pro-inflammatory monocyte subset from among 10⁶ cells were performed (FACSCalibur™; BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo v8.5.2. The percentage of cells or the actual number of cells at baseline were compared to the values 3 months after initiation of probiotic supplementation as well as 4 months after the discontinuation of probiotic treatment.

Quantification of Cytokines before and after a Lipopolysaccharide (LPS) challenge

Fold changes of cytokine production upon an LPS challenge were compared before and after 3 months of probiotic supplementation. Quantification of plasma cytokines were performed using human inflammation cytometric bead array kits (BD Biosciences, San Jose, CA, USA) and cytometric bead arrays (Human inflammation kit, BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions to simultaneously detect levels of interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70, and tumor necrosis factor (TNF)-α.

Measurement of fecal SCFAs

The concentrations of SCFAs in fecal samples were analyzed using high-performance liquid chromatography in the National Instrumentation Center for Environmental Management at Seoul National University (Seoul, Korea). Feces were prepared in normal saline (300 µl per 1 g of feces). The fecal slurry supernatants were obtained through centrifugation (2,500 rpm for 10 min). SCFAs, including acetic, butyric, propionic, isovaleric, and valeric acids were measured before and 3 months after probiotic supplementation.

Microbiome analysis

Sample DNA extraction and next generation sequencing (NGS)

Bacterial genomic DNA was extracted from stool samples using a QIAamp Fast DNA Stool Mini Kit (Qiagen, Hilden, Germany). DNA extraction was performed after homogenization at 30 s for 1 minute using a TissueLyser system (Qiagen) and quantified using a QUBIT 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). For NGS, 16S rRNA gene amplifications and index PCRs were performed following the Illumina 16S metagenomic Sequencing Library preparation guide (Illumina, San Diego, CA, USA). The V3 and V4 regions of 16S rRNA were amplified using the following primer pair (forward 5’–TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG–3’, reverse 5’–TCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC–3’). Nextera XT index kits (Illumina, San Diego, California, USA), using 8 cycles, were then used to fragment DNA and add adapter sequences onto the DNA template. Each PCR product was purified using AMPure XP beads (Beckman Coulter, Pasadena, CA, USA). The amplicon library was sequenced by the 2×300 bp paired-end method on a Miseq instrument (Illumina) according to the Illumina protocol.

Bioinformatics Analysis

Raw sequencing data were analyzed via QIIME2 (https://docs.qiime2.org/2019.7/) [19]. The fastq files were imported to QIIME2 using the ‘Casava 1.8 paired-end demultiplexed method' and merged by DADA2 [20]. Filter parameters for trimming and truncating using the DADA2 plugin were 0 and 140 to remove low quality regions of sequences. Feature tables and data generation (‘qiime feature-table summarized’, and ‘qiime feature-table tabulate-seqs’), and phylogenetic tree construction (‘qiime phylogeny-align-to-tree-mafft-fasttree’) were then performed. QIIME 2’s statistical analyses were also performed using the diversity plugin (“core-metrics-phylogenetic”, “alpha-group-significance”, and “beta-group-significance”). To perform taxonomic classification, 'Greengenes 13_8 99% OTUs full-length sequences' were used as 16S rRNA gene databases [21, 22].

Statistical analysis

All the analyses were performed using SPSS software, version 25.0 (IBM Corporation, USA). Data are expressed as medians [interquartile ranges] according to the distribution. Continuous variables (baseline, after 3 months) were compared using the Wilcoxon signed-rank test. A p-value < 0.05 was considered significant.

Baseline patient characteristics

Twenty-two patients completed the study. The mean age was 68.1 years and 16 patients (73%) were male. The average time for receiving HD was 8 years and the prevalences of diabetes, hypertension, or histories of gastrointestinal surgeries were 18%, 81.5%, and 22%, respectively (Table 1). Eighty-six percent of patients were taking calcium polystyrene sulfonate and the percentage of patients on various medications, including phosphate binders, antacids, iron, and stool softeners, are reported in Table 2. During the study period, 2 patients received systemic antibiotics: one for community-acquired pneumonia, and the other for calculous cholecystitis.

The effect of probiotic supplementation on the microbiome and microbial metabolites

Faith’s phylogenetic diversity showed no significant changes in richness and evenness after probiotic supplementation (p=0.222 and 0.597) (Fig1 A, B). However, at the genus level, the relative abundance of Bacteroides, Faecalibacterium, Oscillospira, Parabacteroides, Lachnospira, and Akkermansia decreased whereas Bifidobacterium, Ruminococcaceae and Lachnospiraceae increased after probiotic supplementation. (Fig1 C).

Short chain fatty acids

SCFAs from gut bacteria are an important nutrient source for enterocytes and are key mediators of the beneficial effects elicited by the gut microbiome. Probiotic supplementation for 3 months resulted in a significant increase of SCFAs such as acetic, butyric, propionic, and valeric acids in feces (Fig. 2).

Effect of probiotic supplementation on inflammatory responses

Serum levels of CRP, albumin, calcium, phosphate, and intact parathyroid hormone (iPTH) were similar before and after 3 months of probiotic supplementation. Hemoglobin, total white blood cell and monocyte counts were also comparable before and after probiotic supplementation (Table 3). Despite comparable fecal calprotectin levels (data not shown), serum calprotectin, a marker of acute inflammation, decreased significantly after 3 months of probiotic supplementation (Fig. 3A).

We also compared the cytokine production upon LPS stimulation and found that fold increase of IL-6 after LPS stimulation significantly decreased 3 months after probiotic supplementation (Fig. 3B).

Effect of probiotic supplementation on CD14⁺ CD16⁺ pro-inflammatory monocyte subset

We assessed the impact of probiotic supplementation on circulating pro-inflammatory monocytes. Using flow cytometry, monocyte subpopulations were divided into 3 different subsets: classical, intermediate, and nonclassical monocytes according to CD14 CD16 positivity (Fig. 4A). Although the percent monocytes did not change in complete blood count, the actual number of CD14⁺ CD16⁺ proinflammatory, non classical monocytes decreased significantly after 3 months of probiotic supplementation (310 vs. 194/mm², p < 0.05) (Fig. 4B).

Effect of probiotic supplementation on regulatory T-cells

Circulating CD4⁺CD25⁺ regulatory T-cells were identified by flow cytometry (Fig. 5A). The percentage of circulating CD4⁺CD25⁺ Tregs increased from 3.5% at baseline to 8.6% 3 months after initiating probiotic supplementation (Fig. 5B).

Tregs and pro-inflammatory monocytes after discontinuation of probiotic supplementation

The increased percentage of Tregs at 3 months after initiation of probiotic supplementation showed a complete return to baseline levels 4 months after the discontinuation of probiotics (Fig. 6A). The number of pro-inflammatory monocytes that decreased after probiotic supplementation also showed a trend to return to baseline after discontinuation of probiotic supplementation (p = 0.061) (Fig. 6B). However, decreased serum calprotectin level was maintained after discontinuation of probiotics (Fig. 6C).

In this study, we demonstrated that the probiotic combination of B. bifidum BGN4 and B. longum BORI had an anti-inflammatory and immunomodulatory effect in patients undergoing maintenance HD. Supplementation of probiotics for 3 months resulted in increased SCFA levels in feces. Serum calprotectin levels as well as IL-6 response upon an LPS challenge decreased significantly 3 months after initiation of probiotic supplementation, and this anti-inflammatory effect was associated with a decreased number of circulating pro-inflammatory, nonclassical monocytes and an increased percentage of immunomodulatory Tregs. However, this effect on circulating immune cells was only transient and returned to baseline after discontinuation of the probiotics.

Emerging evidence shows that intestinal microbiota play an important role in both normal physiology as well as in acute or chronic inflammatory conditions. Both qualitative and quantitative changes in microbiomes have also been reported in uremic animals as well as in patients. Chen et.al. reported the increase of relative abundance of Enterobacteriaceae, Ruminococcaceae, and Lachnospiraceae families in CKD patients and Sampaio-Maia et.al. showed the decrease of butyrate producing bacteriae such as Roseburia, Faecalibacterium, Clostridium, Coprococcus, and Prevotella in end-stage kidney disease (ESKD) (23,24). However, it is not clear whether the perturbation of microbiomes has a causal relationship with CKD. Although a recent meta-analysis of 7 studies enrolling 8-60 dialysis patients showed the potential beneficial effects of probiotics on inflammation, uremic toxins, and GI symptoms, the mechanisms underlying the beneficial effects remains unclear [23].

CKD has emerged as a major cardiovascular risk factor and chronic inflammation is recognized as an important player. The intestine is the single largest organ of the immune system, harboring the largest number of T-cells and macrophages in our body and thus considered to be potent regulator of systemic immunity. Therefore, it can be hypothesized that pre or probiotics induced beneficial effect might be mediated by effects on immune cells.

We first observed that probiotic supplementation resulted in decreased numbers of pro-inflammatory monocytes. Monocytes are cells of the innate immune system and have heterogeneous phenotypes according to surface expression of CD14 or CD16 proteins [24]. Among them, CD14⁺CD16⁺ are nonclassical monocytes that have been known to invade the endothelium and cause plaque formation in the general population and in patients with CKD [25]. We also demonstrated the expansion of these subsets and also their associations with CRP and vascular stiffness in patients with advanced CKD [26]. Significant decrease of actual number of CD14⁺CD16⁺ nonclassical monocytes after probiotic supplementation could suggest that the anti-inflammatory effect of probiotics could be partially mediated by inhibitory effects on the pro-inflammatory monocyte subset. In addition to monocytes, we compared the percentage and number of circulating Tregs before and after probiotic supplementation and observed that the percentage of CD4⁺ CD25⁺ cells in blood showed a significant increase after 3 months of probiotic supplementation. Mahajan et al., showed that Tregs protect against constant macrophage inflammation and reduce pro-inflammatory cytokine production in murine CKD models [27]. Impaired Treg function was also observed in CKD patients that led to chronic inflammation and subsequent atherosclerosis and cardiovascular diseases [27, 28]. Wang et al., also demonstrated that CKD patients with cognitive dysfunction who had increased percentages of Tregs showed significantly higher mini-mental state examination scores than those with reduced percentages of Tregs [29]. Given that potent immune suppressive function, expansion of circulating Tregs after probiotic supplementation is likely contribute to anti-inflammatory effect in our patients. However, we observed that the increased percentage of Tregs returned to baseline in all patients 4 months after the discontinuation of probiotics. Although statistically insignificant, the number of nonclassical monocytes which decreased after 3 months of probiotics also returned to baseline, showing that the anti-inflammatory, immune modulatory effect of probiotics is only transient.

Unlike other studies, serum CRP level or fecal calprotectin did not show significant difference in our study. Instead, we observed that serum calprotectin levels as well as fold increases of IL-6 after the LPS challenge decreased significantly after probiotic supplementation. Calprotectin is a heterodimeric complex of 2 S100 calcium-binding proteins: myeloid-related protein (MRP)-8 and MRP-14, which are mainly expressed in neutrophils and monocytes. Although calprotectin has been originally known to be a novel biomarker of disease activity in patients with inflammatory bowel disease when measured in feces, recent data suggests that serum calprotectin levels can be a useful biomarker of disease activity in several acute and chronic inflammatory conditions [30–33]. Serum and urine calprotectin have been demonstrated to be associated with the severity of renal injuries and endothelial dysfunction in Henoch-Schönlein purpura as well as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis even if CRP levels are not elevated [34–36]. Although we observed that median calprotectin levels decreased significantly after 3 months of probiotic supplementation, the usefulness of serum calprotectin levels as a sensitive marker of inflammation in patients with CKD or HD requires further examination.

IL-6 has been demonstrated to be an important player in the progression of CKD[37]. It exacerbates inflammation as well as endothelial injury by reducing endothelial nitric oxide synthase (eNOS) and injection of recombinant IL-6 exacerbates atherosclerosis in mice [38]. Our data showing that the fold increase of IL-6 upon LPS challenge significantly decreased after 3 months of probiotic supplementation also supports its anti-inflammatory effect.

Various metabolites produced by intestinal microbiota are important in both normal physiology and in pathological conditions. SCFAs are known to be important in colonocyte survival, maintaining barrier integrity and immune modulation. In contrast, excessive production of trimethylamine (TMA) due to the consumption of an animal protein-rich diet has been shown to be associated with atherosclerosis and cardiovascular diseases. In our study, we observed that the levels of acetic, butyric, propionic, and valeric acids increased significantly after 3 months probiotic supplementation. SCFAs are bacterial fermentation products with pleiotropic functions including lipid regulation, energy metabolism, and immune regulation via interaction with G protein-coupled receptors, histone deacetylases, or direct humoral effects. Given that SCFAs have immunomodulatory effects, it is possible that significantly elevated levels of SCFAs during the probiotic supplementation might be partially responsible for decreased proinflammatory monocytes and expansion of Tregs.

Even though our data showed that probiotics elicited a very potent anti-inflammatory effect , 2 of the patients in our study required hospitalization. One patient was diagnosed with calculous cholecystitis, underwent a laparoscopic cholecystectomy, and was administered systemic antibiotics. The second patient was diagnosed with community acquired pneumonia 1 month of probiotic supplementation and was discharged after 5 days of systemic antibiotic therapy. Although a causal relationship between probiotic use and serious infections in this study was not clear, one should always be aware that excessive suppression of inflammatory responses might increase the risk of infections.

Probiotic combinations of B. bifidum BGN4 and B. longum BORI reduced systemic inflammatory responses and this effect was partially mediated by an increase of Tregs and a decrease of the nonclassical pro-inflammatory monocyte subset. Larger-scale clinical studies testing the components of microbiota or their metabolites and assessing the effects on long-term outcomes in dialysis patients are needed.

HD : hemodialysis

Tregs : regulatory T-cells

CKD : chronic kidney disease

CFU : colony forming units

PCR ; polymerase chain reaction

FDA: food and drug administration

NGS: next generation sequencing

SCFA : short chain fatty acids

iPTH : intact parathyroid hormone

ESKD : end stage kidney disease

ANCA: anti-neutrophil cytoplasmic antibody

CRP : C-reactive protein

eNOS: endothelial nitric oxide synthase

Funding

This study was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education (2017R1A2B1002734)

Conflict of interest

The researcher claims no conflicts of interest.

Ethics approval

The study protocol was approved by the Korea University Medical Center Institutional Review Board (IRB No. 2018AN0346).

Consent to participate

Written informed consent was provided by all participants.

Consent for publication

Consent for pulication was obtained from all authors

Availability of data and material (data transparency)

All data support published claims and comply with field standards.

Authors’ contribution

Eunho Choi, Jihyun Yang,, Sang Kyung Jo : Conception, design, analysis and interpretation of data, Drafting and revising the article, final approval of the version to be published

Myeong Soo Park, Yeoungje Seoung, : analysis abd interpretation of data, revising the article, final approval of the version to be published

Geun-Eog Ji, Se Won Oh, Myung Gyu Kim, Won Young Cho : providing intellectual content and final approval of the version to be published

Silver SA, Harel Z, McArthur E, et al (2017) Causes of Death after a Hospitalization with AKI. Journal of the American Society of Nephrology ASN.2017080882. https://doi.org/10.1681/ASN.2017080882
Zimmermann J, Herrlinger S, Pruy A, et al (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney International 55:648–658. https://doi.org/10.1046/j.1523-1755.1999.00273.x
Amdur RL, Feldman HI, Gupta J, et al (2016) Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 11:1546–1556. https://doi.org/10.2215/CJN.13121215
de Mutsert R, Grootendorst DC, Axelsson J, et al (2008) Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrology Dialysis Transplantation 23:2957–2964. https://doi.org/10.1093/ndt/gfn167
Yang Y, Zhang Y, Xu Y, et al (2019) Dietary methionine restriction improves the gut microbiota and reduces intestinal permeability and inflammation in high-fat-fed mice. Food & Function 10:5952–5968. https://doi.org/10.1039/C9FO00766K
Wu M-J, Chang C-S, Cheng C-H, et al (2004) Colonic transit time in long-term dialysis patients. American Journal of Kidney Diseases 44:322–327. https://doi.org/10.1053/j.ajkd.2004.04.048
Andersen K, Kesper MS, Marschner JA, et al (2017) Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD–Related Systemic Inflammation. Journal of the American Society of Nephrology 28:76–83. https://doi.org/10.1681/ASN.2015111285
Yang J, Lim SY, Ko YS, et al (2019) Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease. Nephrol Dial Transplant 34:419–428. https://doi.org/10.1093/ndt/gfy172
Hill C, Guarner F, Reid G, et al (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. https://doi.org/10.1038/nrgastro.2014.66
Soleimani A, Zarrati Mojarrad M, Bahmani F, et al (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91:435–442. https://doi.org/10.1016/j.kint.2016.09.040
Cha R, Kang SW, Park CW, et al (2017) Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract 36:68–78. https://doi.org/10.23876/j.krcp.2017.36.1.68
Park MS, Kwon B, Ku S, Ji GE (2017) The Efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 Probiotic Treatment in Infants with Rotavirus Infection. Nutrients 9:. https://doi.org/10.3390/nu9080887
Seo JM, Ji GE, Cho SH, et al (2007) Characterization of a Bifidobacterium longum BORI dipeptidase belonging to the U34 family. Appl Environ Microbiol 73:5598–5606. https://doi.org/10.1128/AEM.00642-07
Ji GE (2005) Development of Bifidobacterium sp. BGN4 and BORI with novel probiotic activity. 2005 년도 International Meeting of the Microbiological Society of Korea 81–84
Ku S, Park M, Ji G, You H (2016) Review on Bifidobacterium bifidum BGN4: Functionality and Nutraceutical Applications as a Probiotic Microorganism. International Journal of Molecular Sciences 17:1544. https://doi.org/10.3390/ijms17091544
Ku S, You HJ, Ji GE Enhancement of Anti-tumorigenic Polysaccharide Production, Adhesion, and Branch Formation of Bifidobacterium bifidum BGN4 by Phytic Acid. 6
Yu DS, Jeong H, Lee D-H, et al (2012) Complete genome sequence of the probiotic bacterium Bifidobacterium bifidum strain BGN4. J Bacteriol 194:4757–4758. https://doi.org/10.1128/JB.00988-12
Kim M, Ku S, Kim S, et al (2018) Safety Evaluations of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI. IJMS 19:1422. https://doi.org/10.3390/ijms19051422
Caporaso JG, Kuczynski J, Stombaugh J, et al (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336. https://doi.org/10.1038/nmeth.f.303
Callahan BJ, McMurdie PJ, Rosen MJ, et al (2016) DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583. https://doi.org/10.1038/nmeth.3869
DeSantis TZ, Hugenholtz P, Larsen N, et al (2006) Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 72:5069–5072. https://doi.org/10.1128/AEM.03006-05
An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. - PubMed - NCBI. https://www.ncbi.nlm.nih.gov/pubmed/?term=An+improved+Greengenes+taxonomy+with+explicit+ranks+for+ecological+and+evolutionary+analyses. Accessed 24 Dec 2019
Jia L, Jia Q, Yang J, et al (2018) Efficacy of Probiotics Supplementation On Chronic Kidney Disease: a Systematic Review and Meta-Analysis. Kidney Blood Press Res 43:1623–1635. https://doi.org/10.1159/000494677
Ziegler-Heitbrock L, Ancuta P, Crowe S, et al (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116:e74-80. https://doi.org/10.1182/blood-2010-02-258558
Heine GH, Ortiz A, Massy ZA, et al (2012) Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 8:362–369. https://doi.org/10.1038/nrneph.2012.41
Lee J-W, Cho E, Kim M-G, et al (2013) Proinflammatory CD14+CD16+ monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease. Kidney Research and Clinical Practice 32:147–152. https://doi.org/10.1016/j.krcp.2013.08.001
Mahajan D, Wang Y, Qin X, et al (2006) CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 17:2731–2741. https://doi.org/10.1681/ASN.2005080842
Pastrana JL, Sha X, Virtue A, et al (2012) Regulatory T cells and Atherosclerosis. J Clin Exp Cardiolog 2012:002. https://doi.org/10.4172/2155-9880.S12-002
Wang J, Li X-B, Huang P, et al (2018) Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients. Cell Physiol Biochem 45:281–290. https://doi.org/10.1159/000486809
Azramezani Kopi T, Shahrokh S, Mirzaei S, et al (2019) The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench 12:183–189
Inciarte-Mundo J, Ramirez J, Hernández MV, et al (2018) Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther 20:275. https://doi.org/10.1186/s13075-018-1764-z
Ortega FJ, Sabater M, Moreno-Navarrete JM, et al (2012) Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. European Journal of Endocrinology 167:569–578. https://doi.org/10.1530/EJE-12-0374
Gray RD, Imrie M, Boyd AC, et al (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. Journal of Cystic Fibrosis 9:193–198. https://doi.org/10.1016/j.jcf.2010.01.005
Kawasaki Y, Ohara S, Abe Y, et al (2012) The role of serum myeloid-related protein 8/14 complex in Henoch–Schönlein purpura nephritis. Pediatr Nephrol 27:65–71. https://doi.org/10.1007/s00467-011-1937-3
Martinez Valenzuela L, Draibe J, Quero Ramos M, et al (2018) Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS ONE 13:e0205982. https://doi.org/10.1371/journal.pone.0205982
Pepper RJ, Draibe JB, Caplin B, et al (2017) Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis & Rheumatology (Hoboken, NJ) 69:185–193. https://doi.org/10.1002/art.39814
Klein CL, Hoke TS, Fang W-F, et al (2008) Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney International 74:901–909. https://doi.org/10.1038/ki.2008.314
Huber SA, Sakkinen P, Conze D, et al (1999) Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19:2364–2367. https://doi.org/10.1161/01.atv.19.10.2364

Table 1. Patient demographic characteristics

Age	68.1 (40-84)
Men	16 (73%)
Women	6 (27%)
Body-mass index (kg/m2)	22.76 (17.6-27.5)
Hemodialysis year	8 (1994-2018)
Peritoneal dialysis history	8 (26%)
Kidney transplantation history	2 (9%)
Hypertension	18 (81%)
Heart failure	10 (45%)
Ischemic heart disease	8 (26%)
Gastrointestinal operation history	5 (22%)
Cancer	5 (22%)
Diabetes mellitus	4 (18%)
Liver disease	3 (13%)
Chronic obstructive pulmonary disease	2 (9%)

Table 2. Medications

Potassium binder	19 (86%)
Statin	14 (63%)
Phosphate binder	19 (86%)
Ca containing	9 (40%)
Non- Ca containing	10 (46%)
Oral iron	8 (36%)
Warfarin	4 (18%)
Antacid	3 (13%)
Steroid	3 (13%)
Stool softener	2 (9%)
Antihistamine	1 (4%)

Table 3. Clinical parameters ; baseline and post probiotics supplement

	0 Month (n=22)	3 Month (n=18)	P-value
Hb (g/dL)	10.5 [9.9,11.0]	10.4 [9.9,11.6]	0.563
Platelet (x1000/uL)	176.5 [139.8,192.0]	153.5 [117.0,198.2]	0.765
WBC (x1000/uL)	5900 [5050,7730]	5739±2056	0.247
Neutrophil (%)	60.6 [56.6,64.1]	60.9 [55.3,65.5]	0.751
Lymphocyte (%)	23.5 [20.6,26.7]	23.2 [20.2,27.1]	0.968
Monocytes (%)	9.6 [7.9,11.3]	9.0 [7.9,11.6]	0.588
Eosinophil (%)	4.2 [3.2,6.2]	4.8 [2.7,7.9]	0.490
Basophil (%)	0.7 [0.5,1.0]	0.7 [0.5,1.0]	0.370
CRP-hs (mg/L)	3.8±6.8	1.0 [0.6,7.7]	0.370
BUN Pre-HD (mg/dL)	57.9 [41.1,73.0]	64.8 [47.8,71.5]	1.0
Creatinine (mg/dL)	8.8 [7.5,10.0]	8.5 [7.3,11.7]	0.526
Na (mmol/L)	138.0 [137.7,139.2]	139.0 [135.0,140.0]	0.775
K (mmol/L)	4.5 [4.1,5.4]	5.7 [4.1,5.0]	0.245
Cl (mmol/L)	101.0 [98.0,104.0]	100.5 [98.0,102.5]	0.506
CO2, total (mmol/L)	22.0 [20.8,24.0]	22.5 [19.0,23.3]	0.773
Ca, total (mg/dL)	9.0 [8.3,9.5]	13.3±19.1	0.519
P (mg/dL)	4.8 [3.4,6.1]	5.0 [3.9,6.3]	0.466
Mg (mmol/L)	1.1±0.1	1.1±0.1	0.799
Uric acid (mg/dL)	4.3 [3.7,5.2]	5.1±1.0	0.104
Protein (g/dL)	6.7 [6.5,7.0]	6.8 [6.4,7.1]	0.773
Albumin (g/dL)	4.0 [3.8,4.1]	3.9 [3.7,4.3]	0.095
Total Cholesterol (mg/dL)	115.0 [101.3,129.8]	120.0 [94.3,154.8]	0.360
AST (IU/L)	19.0 [14.5,22.8]	20.0 [13.0,25.3]	0.760
ALT (IU/L)	14.5 [11.0,18.0]	14.0 [12.0,18.3]	0.647
ALP (IU/L)	92.5 [69.5,118.3]	87.5 [70.3,106.5]	0.177
GGT (IU/L)	20.5 [12.5,28.5]	20.5 [13.0,29.0	0.061
Bilirubin, total (mg/dL)	0.5 [0.4,0.7]	0.5 [0.5,0.8]	0.268
Glucose (mg/dL)	97.0 [84.0,108.0]	96.5 [90.8,109.8]	0.525
KT/V	1.67 ± 0.24	1.72 ± 0.25	0.223
URR	75.07 ±5.27	76.2 ± 4.71	0.091
Body weight	61.6 ± 11.4	61.2 ± 11.4	0.808

Download PDF

Version 1

posted

You are reading this latest preprint version

Probiotic supplementation reduces systemic inflammation in dialysis patients: the effect on circulating regulatory T-cells and pro-inflammatory monocytes

Status:

Version 1

Abstract

Figures

Introduction

Material And Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Status:

Version 1